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Abstract
Background: Aside from chemotherapy utilization, limited data are available on the relationship between gene
expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and
additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast
imaging exams in women under age 65 years.
Methods: Data from five state cancer registries were linked with claims data and GEP results. We assessed variables
associated with survivorship care outcomes in an incident cohort of 5014 commercially insured women under age
65 years, newly diagnosed with stage I or II hormone-receptor-positive, human epidermal growth factor receptor 2
(HER2) non-positive breast cancer from 2006 to 2010.
Results: Among tested women, those with high Oncotype DX® Breast Recurrence Score® (RS) were significantly less
likely to initiate endocrine therapy than women with low RS tumors (OR 0.40 (95% CI 0.20 to 0.81); P = 0.01). Among
all test-eligible women, receipt of Oncotype DX testing was associated with a greater likelihood of endocrine
therapy initiation (OR 2.48 (95% CI 2.03 to 3.04); P <0.0001). The odds of initiation were also significantly higher for
tested vs. untested women among women who did not initiate chemotherapy within six months of diagnosis
(OR 3.25 (95% CI 2.53 to 4.16)), with no effect in women who received chemotherapy. Discontinuation and
adherence and breast imaging exams were unrelated to tested status or RS.
Conclusions: Lower endocrine therapy initiation rates among women with high RS tumors and among untested
women not receiving chemotherapy are concerning, given its established efficacy. Additional research is needed to
suggest mechanisms to close this gap.
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Background
Women with estrogen-receptor-positive (ER+), early-
stage disease represent more than half of the almost
250,000 women newly diagnosed with breast cancer each
year [1–4]. Clinical guidelines for these women now in-
clude results from genomic expression profiling (GEP)
tests, such as the Oncotype DX® Breast Recurrence Score®
(RS) [5–7], to refine recurrence risk estimates and guide
treatment selection. These guidelines have led to broad
dissemination and integration of such tests into routine
oncology care [8–10]. In the absence of genomic profiling,
combined chemo-endocrine therapy is recommended for
most of these patients [11]. However, in the presence of a
low RS, patients who receive this result (almost 50% of pa-
tients) can receive endocrine therapy alone, safely forgoing
chemotherapy and its side effects [6]. Approximately 25%
of patients receive high-risk results and can be prompted
to act on this risk and receive chemotherapy to maximize
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survival [12]. Previous studies show that receipt of chemo-
therapy generally follows these recommendations, with
some observed variations [9, 13, 14].
There have been no studies of other possible and un-
intended effects of GEP testing on breast cancer care.
For example, we do not know whether survivorship care,
including both endocrine therapy and breast imaging for
recurrence or progression, received by this growing
group of breast cancer survivors is affected by GEP test-
ing. All women eligible for Oncotype DX testing should
also receive endocrine therapy over at least a 5-year period
after the conclusion of initial surgery (and chemotherapy
or radiotherapy if given) [7]. It is estimated that approxi-
mately 10–30% of all women with hormone-receptor-
positive breast cancer do not initiate endocrine therapy
[15–17] and 40–60% may not complete the full 5-year
regimen of therapy [18–21]. Likewise, 21% of all women
with early-stage breast cancer do not receive breast im-
aging tests for recurrence in the year following diagnosis
[22], even though practice guidelines recommend an an-
nual follow-up mammogram after initial surgery [23, 24].
Therefore, the objective of this study was to measure the
rates of initiation, discontinuation and non-adherence to
endocrine therapy and also the receipt of breast imaging
(mammography and breast magnetic resonance imaging
(MRI)), comparing variations in these care patterns by
test result, and differences between GEP-tested and
untested women.
Methods
Patient selection and study cohort
Details of data linkages have been presented previously
[10]. Briefly, our linked database consists of five state
cancer registries containing clinical and pathological
variables linked with claims data from HealthCore’s
Integrated Research Database (HIRDSM). HealthCore Inc.
(Wilmington, DE, USA) is an independent subsidiary to
Anthem, Inc., which is an independent licensee of the Blue
Cross and Blue Shield Association. We linked RS results
through collaboration with Genomic Health, the patent
holder of the Oncotype DX test.
We conducted a retrospective cohort study of 6737
women who were aged 24–63 years and were diagnosed
with stage I or II hormone-receptor-positive human epi-
dermal growth factor receptor 2 (HER2) non-positive
breast cancer between 2006 and 2010. We excluded 31
women who initiated endocrine therapy prior to their
breast cancer diagnosis, 1179 women who were diagnosed
while without medical insurance eligibility and did not ini-
tiate endocrine therapy within 6 months from the date of
diagnosis, 265 women with two coverage gaps or a gap
longer than 6 months or a follow up period shorter than
3 months. Finally because oral medication is the most
common form of endocrine therapy, we excluded 248
women who did not have pharmacologic coverage when
diagnosed and who had not initiated drug coverage within
4 months of initial diagnosis. Thus, our final cohort
for this analysis included 5014 women eligible for
GEP testing, who were followed through 30 April 2012 or
the end of medical coverage, whichever was earlier.
Median follow-up time was 2.68 years. The sample sizes
differed in some of the analyses, and this reflects incom-
plete data on the study variables. Only participants with
complete data were retained.
Study measures
Endocrine therapy initiation was defined as receiving
prescriptions for tamoxifen, letrozole, anastrozole, or
exemestane within 18 months post breast cancer diagnosis.
GEP status and RS were identified by a linkage between
HealthCore and Genomic Health test data for Anthem
members with breast cancer whose GEP testing is per-
formed by Genomic Health. RS results were categorized as
low (RS <18), intermediate (RS = 18–30) or high (RS >30)
as defined by the original clinical validation studies
for the assay [25]. From registry data we obtained age
at diagnosis, race-ethnicity, marital status, date of
diagnosis and diagnosis of prior primary cancers other
than breast cancer, including non-melanoma skin can-
cers. Staging was created using the American Joint
Committee on Cancer Breast Cancer Staging (version
6 or 7, depending on the diagnosis year) [26].
We obtained estrogen receptor (ER), progesterone re-
ceptor (PR), HER2, nodal status and histological grade
from registry data. We grouped women with ER+ and
PR+ cancer vs. women having either PR+ or ER+ tumors
(but not both). We compared borderline HER2 status
(immunohistochemical score (IHC) 2+) and those with
unknown status to those with HER2-negative cancer.
HER2 status was derived using the SEER Collaborative
Stage Site-Specific Factor 15 (positive/negative/border-
line/unknown). We also compared those with no cancer
in the lymph nodes (nodal status (N)0) to those with
cancer in the lymph nodes <2 mm in size that can only
be seen under a microscope (N1mic) and those with
cancer of at least 2 mm in size in at least one of three
axillary lymph nodes (N1). Well-differentiated and mod-
erately differentiated tumors were compared to poorly
differentiated or undifferentiated tumors. From HIRD we
derived 31 comorbid conditions 1 year prior to breast can-
cer diagnosis based on the Elixhauser comorbidity index
[27]. For each condition, we used a commonly applied al-
gorithm that required an inpatient diagnosis and/or at
least two outpatient diagnosis codes at least 30 days apart,
to minimize false positives. Finally, members’ residential
5-digit zip codes were linked to derive sociodemographic
data based on the 2007–2011 American Community
Survey of US Census, including median household income
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Table 1 Characteristics of selected cohort and relationship with endocrine initiation and adherence
Initiation Adherence
Selected cohort Selected cohort
Number Row % P Number Row % P
Total 5014 84 4218 61
Recurrence score <0.0001 0.13
Low (<18) 821 91 745 64
Intermediate (18–30) 621 91 566 63
High (>30) 165 83 137 66
No oncotype 3407 81 2770 60
Year diagnosed 0.06 0.001
2006–2007 1929 85 1639 58
2008–2009 2097 83 1734 63
2010 988 86 845 65
Age at diagnosis, years 0.14 <0.001
24–39 361 81 293 51
40–49 1621 83 1350 60
50–59 2091 85 1784 63
60–63 941 84 791 64
Race-ethnicity 0.10 0.004
NH white 4263 84 3593 62
NH black 188 79 148 49
Hispanic 205 82 168 58
Other/unknown 358 86 309 66
Marital status 0.03 0.002
Not married 1427 82 1177 57
Married 3507 85 2978 63
Missing 80 79 63 63
Prior cancer 0.77 0.24
No 4766 84 4011 61
Yes 248 83 207 61
State 0.04 0.14
CA 1985 83 1642 61
GA 930 83 771 58
KY 483 87 421 62
NY 771 86 662 65
OH 845 85 722 62
Area 0.76 0.15
Rural 254 83 212 57
Urban 4703 84 3959 62
Missing 57 82 47 62
Median household income 0.23 0.03
1 (lowest) 952 802 60
2 921 84 766 61
3 1071 83 892 58
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(in quintiles) and urban vs. rural location. Chemotherapy
was defined as receipt of any guideline-recommended
chemotherapeutic agent after surgical resection that was
initiated within 6 months of primary surgery.
Receipt of follow-up imaging to assess recurrence or
spread of breast cancer was defined using Current Proced-
ural Terminology (CPT)-4 and Healthcare Common
Procedure Coding System (HCPCS) codes corresponding
to screening mammography, diagnostic mammography,
ultrasound imaging or MRI of the breast within the period
6–26 months after initial diagnosis.
Statistical analysis
We first examined the bivariate relationship between
endocrine therapy initiation and each independent pre-
dictor variable, using two-sided chi-square and t tests as
Table 1 Characteristics of selected cohort and relationship with endocrine initiation and adherence (Continued)
4 999 83 864 62
5 (highest) 1014 86 847 66
Missing 57 84 47 62
Stage 0.001 0.44
I 3035 83 2504 61
II 1979 87 1714 62
Nodal involvement 0.001 0.50
N0 3767 83 3122 61
N1mic 325 87 292 61
N1 922 90 804 63
HER2 status 0.66 0.35
Negative 2283 84 1928 62
Borderline 55 87 48 52
Unknown 2676 84 2242 61
Hormone receptor status <0.001 0.89
Both ER and PR positive 4299 85 3664 61
Only ER or PR positive 715 77 554 61
Histological grade 0.04 0.17
1–2 3737 85 3175 62
3 1076 82 887 59
Missing 201 78 156 58
One-year comorbidities 0.17 0.08
0 4395 84 3709 62
1 or more 619 82 509 58
Surgery type 0.16 0.45
Breast-conserving surgery 3049 84 2569 62
Mastectomy 1956 85 1642 61
Unknown/missing 9 78 7 71
Endocrine therapy <0.001
Tamoxifen only – 1512 58
AIs only – 1930 65
Tamoxifen and AIs – 776 58
Adjuvant chemotherapy <0.001 0.86
No 2585 2084 61
Yes 2429 2134 61
Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least
2 mm in size in at least one of three axillary lymph nodes. NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor, PR progesterone
receptor, AI aromatase inhibitor
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Table 2 Multivariable models of variables associated with endocrine initiation among women tested by Oncotype Dx (N = 1528) and
women who were eligible for testing by Oncotype Dx (N = 4674)
Oncotype Dx-tested Oncotype Dx-eligible








Year diagnosed 0.13 0.004
2006–2007 (ref)
2008–2009 0.74 (0.49–1.13) 0.74 (0.61–0.89)
2010–2012 1.17 0.65–2.09) 0.89 (0.70–1.15)
Age at diagnosis 0.20 <0.001
24–39 0.49 (0.24–1.01) 0.59 (0.43–0.82)
40–49 0.73 (0.48–1.11) 0.74 (0.60–0.90)
50–59 (ref)
60–63 0.80 (0.49–1.30) 1.01 (0.80–1.27)
Race-ethnicity 0.06 0.19
NH white (ref)
NH black 3.62 (0.83–15.81) 0.92 (0.61–1.38)
Hispanic 0.62 (0.27–1.41) 0.89 (0.60–1.33)
Other 2.52 (0.89–7.13) 1.44 (1.01–2.06)
Marital status 0.16 0.12
Married (ref)
Not married 0.76 (0.52–1.11) 0.87 (0.72–1.04)
Prior cancer 0.65 0.84
No (ref)
Yes 1.21 (0.52–2.80) 1.04 (0.71–1.53)
State 0.004
CA (ref)
GA 0.62 (0.32–1.20) 1.15 (0.85–1.55)
KY 1.73 (0.72–4.14) 1.71 (1.19–2.47)
NY 1.05 (0.50–2.19) 1.60 (1.16–2.20)
OH 1.20 (0.58–2.50) 1.45 (1.05–2.00)
Area 0.74 0.70
Rural (ref)
Urban 1.17 (0.47–2.92) 1.08 (0.74–1.56)
Median household income 0.24 0.07
1 (lowest (ref))
2 1.23 (0.68–2.22) 0.96 (0.74–1.26)
3 1.00 (0.57–1.76) 0.97 (0.74–1.26)
4 1.84 (0.97–3.49) 1.35 (1.02–1.82)
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appropriate, to test statistical significance. We then
assessed initiation using a multivariable logistic regres-
sion model with endocrine therapy initiation within
18 months as the binary dependent variable. One model
was run among the entire cohort of those considered eli-
gible for GEP testing to assess the association between
GEP testing and endocrine therapy initiation, adjusting for
all other variables. Next, a similar model was run among
only GEP-tested women to assess the association between
RS results (as both categorical and continuous measures)
and initiation of endocrine therapy. Prior to running our
final multivariable model, we tested several, clinically di-
rected hypothesized interactions (e.g., tested status × receipt
of chemotherapy) individually when added to the main ef-
fects model. We only report those interaction terms that
met our criteria for statistical significance (type I error of
0.05) in the final multivariable model. Models only included
women who had complete information on all predictors
(93% of all eligible women, 95% of all tested women).
Discontinuation of therapy was defined as having no
prescription refill at least 45 days after all pills would be
estimated to have been taken: 45 days was chosen
Table 2 Multivariable models of variables associated with endocrine initiation among women tested by Oncotype Dx (N = 1528) and
women who were eligible for testing by Oncotype Dx (N = 4674) (Continued)
5 (highest) 1.10 0.59–2.07) 1.01 (0.75–1.36)
Stage 0.14 0.52
I (ref)
II 0.71 (0.45–1.12) 0.92 (0.71–1.19)
Nodal involvement 0.22 0.10
N0 0.42 (0.14–1.26) 0.87 (0.64–1.17)
N1mic 0.69 (0.18–2.62) 1.40 (0.91–2.17)
N1 (ref)
HER2 status 0.82 0.33
Negative 0.89 (0.49–1.62) 1.21 (0.55–2.92)
Borderline 0.63 (0.13–3.06) 1.26 (0.94–1.56)
Unknown (ref)
Hormone receptor status <0.001
ER and PR both positive (ref)
Only ER or PR positive 0.80 (0.45–1.42) 0.58 (0.47–0.72)
Histological grade 0.52 <0.001
1–2 (well/moderately differentiated (ref)
3 (poorly or not differentiated) 1.18 (0.71–1.96) 0.68 (0.56–0.84)
One year comorbidities 0.57 0.51
0 (ref)
1 or more 0.86 (0.52–1.43) 0.92 (0.72–1.18)
Surgery type 0.74 0.42
Breast-conserving surgery (ref)





No Yes – 3.25 (2.53–4.16)
No –
Yes Yes – 1.35 (0.96–1.90)
No –
Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node cancer that can only be seen under a microscope (<2 mm in size); N1 cancer at least
2 mm in size in at least one of three axillary lymph nodes. ref reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2, ER estrogen receptor,
PR progesterone receptor
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because the majority of all prescription fills in our sam-
ple (88%) were for a 30-day supply. We conducted
multivariate survival analysis using Cox proportional
hazard models with competing risks, to identify sociode-
mographic and clinical variables associated with time to
discontinuation. The time of discontinuation was defined
as the date of the last fill before the qualified gap, plus the
day supply of that fill (usually 30 or 60) plus any pills that
remained from previously filled prescriptions.
Competing risk due to disease recurrence or metastatic
spread was defined using surrogate variables of inpatient
and outpatient claims reflecting either a diagnosis of sec-
ondary breast cancer at least 1 year after primary diagnosis
or the initiation of a new cycle of chemotherapy following
initiation of endocrine therapy. Women were censored at
the date of discontinuation of medical and/or pharmacy
insurance coverage, or the end of available claims data
(30 April 2012), whichever was earlier. We created
two Cox proportional hazards models as described
previously, comparing tested and untested women
with respect to discontinuation, and then the associ-
ation of GEP test results (RS) with discontinuation.
Non-adherence to therapy was defined as a medication
possession ratio (MPR) of <80%, where MPR = the total
day’s supply/the total number of days from initiation to
the end of follow up, censoring those who had discontin-
ued therapy [18, 28]. Associations between patient-level
clinical, sociodemographic, or group-level socioeconomic
variables and non-adherence were assessed using a multi-
variable logistic regression model.
We assessed receipt of at least one breast imaging
exam (as defined above) during the period 6–26 months
post diagnosis using a logistic regression model similar to
the endocrine therapy initiation model. This time range
was selected to be as conservative as possible in identifying
such exams. We controlled for type of surgery in this
model (breast conserving surgery vs. unilateral mastectomy,
and exclusion of women who had bilateral mastectomy).
All tests were two-sided and we considered a P
value <0.05 as significant. We report adjusted odds ratios
and 95% confidence intervals (CI) from logistic regression
and adjusted hazard ratios with 95% CI for Cox models.
All calculations were done using SAS 9.3 (Cary, NC, USA).
Results
In the study cohort (N = 5014), 1607 women (32%) re-
ceived GEP testing (Table 1). Most of these women had
either low (N = 821) or intermediate (N = 621) risk tu-
mors. The sample was primarily white, previously un-
affected by cancer, had no comorbidity and resided in
urban areas. Most received breast-conserving surgery as
their primary treatment (N = 3049).
Endocrine therapy initiation
We analyzed the relationship between GEP test results
and endocrine therapy initiation in GEP-tested women
(N = 1528): 10% of tested women did not initiate ther-
apy. As seen in Table 2, after adjusting for all other vari-
ables, the RS was significantly associated with initiation
(P = 0.02) in this model. As compared with women with
low RS (91% of women), women with high RS results (83%
of women) were significantly less likely to initiate endo-




































Tested Status x Chemotherapy Initiated by Six Months
Fig. 1 Adjusted odds of being tested was significantly higher for tested vs. untested women among women who did not initiate chemotherapy
within six months of diagnosis. There were no significant differences in initiation by tested status in women had initiated chemotherapy within
six months of diagnosis
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Among all test-eligible women with complete data
(N = 4674), 16% of women did not initiate therapy.
Receipt of Oncotype DX testing was associated with
significantly greater likelihood of endocrine therapy initi-
ation (10% vs. 19% non-initiation; OR 2.48 (95% CI 2.03 to
3.04); P <0.001). Younger age (P < 0.0001), being diagnosed
after 2007 (P = 0.004), ER or PR positivity vs. ER and PR
positivity (OR 0.58 (95% CI 0.47 to 0.72); P < 0.001), and
poorly differentiated or undifferentiated tumor grade vs.
well-differentiated or moderately differentiated grade (OR
0.68 (95% CI 0.56 to 0.84); P < 0.001) were associated
with lower odds of initiation, while being outside our
reference site of California (P < 0.004) was independently
associated with greater odds of initiation of endocrine
therapy. There also was a significant interaction between
receipt of chemotherapy and tested status (P < 0.001).
The adjusted odds of initiating endocrine therapy was sig-
nificantly higher in tested vs. untested women among
those women who did not receive adjuvant chemotherapy
(OR 3.25 (95% CI 2.53 to 4.16)). There were no significant
differences in initiation by tested status in women who
had initiated chemotherapy within 6 months of diagnosis
(OR 1.35 (95% CI 0.96 to 1.90)); Fig. 1).
Discontinuation
Discontinuation overall, by tested status and by RS cat-
egory among tested women, is presented in Fig. 2. The
proportion of patients who continued therapy during the
study period was similar across tested vs. untested
women and across RS category.
Among tested women, RS category was not associated
with discontinuation. In the total cohort of eligible
women (Table 3), tested status was not significantly re-
lated to discontinuation of endocrine therapy. Younger
age (P = 0.002), being diagnosed after 2007 (P < 0.001),
being non-Hispanic Black vs. white (hazard ratio (HR)
1.32 (95% CI 1.08 to 1.61)), unmarried vs. married (HR
1.11 (95% CI 1.02 to 1.21); P = 0.01) and having one or
more comorbidities vs. none (HR 1.17 (95% CI 1.03 to
1.32); P < 0.01) were associated with greater odds of
discontinuation. Being outside our reference site of
California (P < 0.001), having higher household income
(P < 0.001), and receiving aromatase inhibitors (AIs) (HR
0.77 (95% CI 0.70 to 0.87)) or a combination of AIs and
tamoxifen (HR 0.76 (95% CI 0.68 to 0.85); P < 0.001) vs.
tamoxifen alone were associated with completion of
therapy within the time of our analysis.
Non-adherence
Our model of non-adherence among tested women sug-
gested that RS category was not associated with non-
adherence. In our model of non-adherence to endocrine
therapy among test-eligible women (Table 4), tested sta-
tus also was unrelated to adherence.
Breast imaging
As seen in Table 5, RS was unrelated to our imaging
outcomes.
Discussion
To our knowledge, this is the first study to assess endo-
crine therapy use and survivorship care among women
who are eligible to receive Oncotype Dx testing, a group
that represents more than half of all new breast cancer




































































































Fig. 2 Kaplan-Meier curves for continuation of endocrine therapy
among (a) all test-eligible women, (b) by tested status, and (c) by RS
category
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demographic and group-level variables, including the re-
ceipt of testing and test results, are associated with initi-
ation of endocrine therapy in women under age 65 years
with early-stage breast cancer, with additional variables
associated with continuation and adherence.
Overall, non-initiation rates were comparable to the
higher estimates of non-initiation seen in the literature
[15–17]. Lower rates of initiation were observed among
women having demographic or tumor characteristics as-
sociated with more aggressive disease (high RS and
tumor grade, and younger age). While many of these pa-
tients with aggressive disease would have received
chemotherapy, and this variable was included in our
model, continuity of care for women receiving endocrine
therapy following completion of chemotherapy could
Table 3 Multivariable model of variables associated with
discontinuation of endocrine therapy among women who were
eligible for Oncotype Dx testing (N = 3949)










































Table 3 Multivariable model of variables associated with
discontinuation of endocrine therapy among women who were









Hormone receptor status 0.69
ER and PR both positive (ref)
Only ER or PR positive 1.02 (0.91–1.15)
Histological grade 0.17
1–2 (well/moderately differentiated) (ref)
3 (poorly or not differentiated) 1.07 (0.97–1.18)
One year comorbidities 0.01
0 (ref)






AIs only 0.77 (0.70–0.87)




Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node
cancer that can only be seen under a microscope (<2 mm in size); N1 cancer
at least 2 mm in size in at least one of three axillary lymph nodes. ref
reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2,
ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor
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serve as a partial explanation [17, 29]. An additional
disease-related explanation could be that some high-risk
patients could have tumors with low ER positivity, de-
fined as ER positivity between 1 and 10% [30, 31], given
that prior guidelines did not recommend endocrine ther-
apy in this group and there remains some uncertainty
about the role of endocrine therapy in this setting [32, 33].
Receptor positivity is reported in local pathology reports
and through the Oncotype Dx test report, though we did
not assess the concordance of these [34].
Patient’s misperceptions of the need for endocrine
therapy or their interest in avoiding additional side
effects of endocrine therapy following the receipt of
chemotherapy could serve as an additional barrier to ini-
tiation. Some studies have found that women who
Table 4 Multivariable model of variables associated with
adherence to endocrine therapy among women who were
eligible for Oncotype Dx testing (N = 3949)










































Table 4 Multivariable model of variables associated with
adherence to endocrine therapy among women who were









Hormone receptor status 0.96
ER and PR both positive (ref)
Only ER or PR positive 0.99 (0.82–1.21)
Histological grade 0.22
1–2 (well/moderately differentiated) (ref)
3 (poorly or not differentiated) 1.11 (0.94–1.31)
One-year comorbidities 0.006
0 (ref)






AIs only 0.77 (0.64–0.92)




Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node
cancer that can only be seen under a microscope (<2 mm in size); N1 cancer
at least 2 mm in size in at least one of three axillary lymph nodes. ref
reference, NH non-Hispanic, HER2 human epidermal growth factor receptor 2,
ER estrogen receptor, PR progesterone receptor, AI aromatase inhibitor
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receive chemotherapy have higher rates of initiation than
chemotherapy-naïve women [17, 35], but others have
found no such association [29, 36]. Our cohort and data-
set differ in several ways from those in previous studies.
The women in our cohort were younger (under age
65 years) than those in previous studies. Also, some
studies have primarily used patient self-report data on
the outcome of initiation and on receipt of chemother-
apy. This could result in measurement differences that
would impact the outcome across studies.
Our finding of non-initiation is of particular concern,
given that the high RS is based on the assumption of re-
ceipt of endocrine therapy [12, 25]. Therefore, in the ab-
sence of endocrine therapy, this risk of recurrence may be
even higher. Given the efficacy of endocrine therapy in all
women with hormone-receptor-positive early-stage breast
cancer, our results suggest that there is potential for im-
proved adherence and reduced morbidity and mortality in
those women with high RS, who comprise approximately
10% of tested women within this subgroup.
Further, among chemotherapy-naïve women, untested
women were less likely to initiate endocrine therapy.
This, in light of our findings of significantly higher initi-
ation rates among tested vs. untested women, implies
lower quality of care and non-adherence to clinical
guidelines in the care of some women. Alternately, these
differences in the tested vs. untested group may reflect a
strong selection effect for testing, as we have previously
reported that clinical markers were strongly associated
with test use [10].
Unlike our findings on the initiation of endocrine ther-
apy, disease with a high RS did not impact rates of dis-
continuation and nonadherence. We did find that
discontinuation and nonadherence varied by several
demographic and clinical factors, including age, race and
comorbidity. Our study is consistent with previous find-
ings showing that younger women were more likely to
discontinue endocrine therapy than older women [18].
Numerous studies have identified variation in receipt of
endocrine therapy by race and ethnicity [18, 37–39].
In addition, women who received only tamoxifen were
less likely to continue and adhere than women on other
regimens. Previous studies, most of which included an
overall older cohort than that in the current study, dem-
onstrate lower adherence among women who are on
tamoxifen [18] or no effect [29, 36]. Our findings could
reflect the comparatively younger age of our cohort. Side
effects can limit women’s adherence and continuation of
endocrine therapy and these side effects vary across
women. Initial conversations about what side effects to
expect [40] and ongoing communication between pa-
tients and their medical oncologists about side effects
and options for switching may promote adherence [41].
While utilizing claims data comes with numerous
strengths, it also comes with some limitations. These in-
clude the potential for coding inaccuracies, the need to
censor patients based on their insurance coverage and
presence in the dataset, and the overall generalizability
of data outside of an insured USA population. Further,
determination of recurrence or metastases using claims-
based data is a known challenge [42]. Our study in-
cluded a relatively small proportion of non-white and
Hispanic participants. Our study also was limited by the
high proportion of patients with unknown HER2 status,
because most registries did not collect this element prior
to 2010. We were unable to account for certain variables
possibly related to survivorship care, such as the rates
and severity of side effects from endocrine therapy, re-
ceipt of care in academic centers vs. community centers
and other unmeasured patient-level variables.
Finally, our study may have limited generalizability to
clinical practice in the USA because we were only able
to include women under age 65 years with commercial
health insurance in five USA states, but this also allowed
Table 5 Multivariable model of variables associated with receipt
of two or more breast imaging exams in the 6–26 months after
diagnosis among tested women (N = 731)
OR (95% CI) P
Recurrence score 0.06
Low or intermediate (ref)
High 0.49 (0.23–1.03)










No (ref) 1.29 (0.77–2.15)
Histological grade 0.84
1–2 (well/moderately differentiated) (ref)







Nodal involvement: N0 no cancer in the lymph nodes; N1mic lymph node
cancer that can only be seen under a microscope (<2 mm in size); N1 cancer
at least 2 mm in size in at least one of three axillary lymph nodes
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us to contribute to a more specific understanding of
breast cancer care among younger women. Our results
reflect regional variation that might not reflect use in
non-commercially insured women, uninsured women,
and those in other states in the USA.
Conclusion
The primary strength of our study is that it is among the
first to assess the relationship between GEP testing and
test results with breast cancer care in patients who are
eligible for Oncotype Dx testing. Our results suggest that
in addition to previously reported associations between
GEP testing and receipt of chemotherapy [14], there is an
important association between GEP testing and the initi-
ation of endocrine therapy. Additional studies should as-
sess potential explanations for this variation and explore
possible interventions to increase initiation of this effica-
cious therapy among all eligible women with hormone-
receptor-positive breast cancer.
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